|0.3802 0.007 (1.79%)||11-28 14:51|
|Targets||6-month :||0.6||1-year :||0.77|
|Resists||First :||0.51||Second :||0.66|
|Supports||First :||0.28||Second :||0.24|
|MAs||MA(5) :||0.37||MA(20) :||0.4|
|MA(100) :||0.81||MA(250) :||1.68|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||50.4||D(3) :||40.3|
|52-week||High :||3.75||Low :||0.28|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SGMO ] has closed below upper band by 35.3%. Bollinger Bands are 56.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||0.4 - 0.4||0.4 - 0.41|
|Low:||0.35 - 0.35||0.35 - 0.35|
|Close:||0.37 - 0.37||0.37 - 0.38|
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||177 (M)|
|Shares Float||159 (M)|
|Held by Insiders||14.4 (%)|
|Held by Institutions||65.6 (%)|
|Shares Short||11,590 (K)|
|Shares Short P.Month||9,110 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0.75|
|Profit Margin||-123.9 %|
|Operating Margin||-655.6 %|
|Return on Assets (ttm)||-16.5 %|
|Return on Equity (ttm)||-112.4 %|
|Qtrly Rev. Growth||-64.5 %|
|Gross Profit (p.s.)||-0.79|
|Sales Per Share||1.13|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-231 (M)|
|Levered Free Cash Flow||-105 (M)|
|Price to Book value||0.5|
|Price to Sales||0.33|
|Price to Cash Flow||-0.3|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|